Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis

Stock Information for Cardiol Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cardiol Therapeutics Inc.

Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis
Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option
Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares
Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares
Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares
Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024
Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders
Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.